NovaBay Pharmaceuticals (NYSE:NBY) Coverage Initiated by Analysts at

Research analysts at began coverage on shares of NovaBay Pharmaceuticals (NYSE:NBYGet Rating) in a research report issued on Sunday. The brokerage set a “hold” rating on the stock.

NovaBay Pharmaceuticals Stock Up 10.6 %

Shares of NovaBay Pharmaceuticals stock opened at $0.09 on Friday. The firm has a market cap of $5.75 million, a PE ratio of -0.80 and a beta of 2.83. The business’s fifty day simple moving average is $0.12 and its 200-day simple moving average is $0.20. NovaBay Pharmaceuticals has a 52 week low of $0.07 and a 52 week high of $0.59.

NovaBay Pharmaceuticals (NYSE:NBYGet Rating) last announced its quarterly earnings data on Thursday, August 11th. The company reported ($0.04) earnings per share for the quarter. NovaBay Pharmaceuticals had a negative net margin of 46.42% and a negative return on equity of 36.85%. The firm had revenue of $3.05 million during the quarter. As a group, equities analysts expect that NovaBay Pharmaceuticals will post -0.1 earnings per share for the current year.

NovaBay Pharmaceuticals Company Profile

(Get Rating)

NovaBay Pharmaceuticals, Inc, a pharmaceutical company, develops and sells eyecare and skincare products in the United States and internationally. It offers Avenova, a solution for removing foreign materials, including microorganisms and debris from skin around the eye, such as the eyelid; and wound care products under the NeutroPhase and PhaseOne brands.

Further Reading

Receive News & Ratings for NovaBay Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NovaBay Pharmaceuticals and related companies with's FREE daily email newsletter.